Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury

Journal of Hepatology

Volumn 63, Issue 1, 2015, Pages 148-155

  Lai, Rongtao ^a   Xiang, Xiaogang ^a   Mo, Ruidong ^a   Bao, Rebecca ^b   Wang, Peng ^a   Guo, Simin ^a   Zhao, Gangde ^a   Gui, Honglian ^a   Wang, Hui ^a   Bao, Shisan ^b   Xie, Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

DILI; IL 22; Protection; Th17 cells; Th22 cells

Indexed keywords

ANTIBIOTIC AGENT; ANTIULCER AGENT; CARDIOVASCULAR AGENT; CHINESE DRUG; CONTRACEPTIVE AGENT; GLYCYRRHIZIC ACID; INTERLEUKIN 22; NONSTEROID ANTIINFLAMMATORY AGENT; URSODEOXYCHOLIC ACID; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ADULT; ARTICLE; CELL COUNT; CELL FUNCTION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; LIVER FUNCTION; LIVER REGENERATION; MALE; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; TH22 CELL; TOXIC HEPATITIS; DRUG EFFECTS; FOLLOW UP; IMMUNOLOGY; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKINS; LIVER; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TH17 CELLS;

EID: 84931577807     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.02.004     Document Type: Article

References (40)

1. G. Ostapowicz, R.J. Fontana, F.V. Schiodt, A. Larson, T.J. Davern, and S.H. Han Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States Ann Intern Med 137 2002 947 954
2. N. Kaplowitz Drug-induced liver injury Clin Infect Dis 38 2004 S44 S48
3. S.R. Knowles, J. Uetrecht, and N.H. Shear Idiosyncratic drug reactions: the reactive metabolite syndromes Lancet 356 2000 1587 1591
4. M. Mennicke, A. Zawodniak, M. Keller, L. Wilkens, N. Yawalkar, and F. Stickel Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation Am J Transplant 9 2009 2197 2202
5. M.P. Holt, L. Cheng, and C. Ju Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury J Leukoc Biol 84 2008 1410 1421
6. A.B. Imaeda, A. Watanabe, M.A. Sohail, S. Mahmood, M. Mohamadnejad, and F.S. Sutterwala Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome J Clin Invest 119 2009 305 314
7. X. Zhu, J. Li, F. Liu, and J.P. Uetrecht Involvement of T helper 17 cells in D-penicillamine-induced autoimmune disease in Brown Norway rats Toxicol Sci 120 2011 331 338
8. N.M. Steuerwald, D.M. Foureau, H.J. Norton, J. Zhou, J.C. Parsons, and N. Chalasani Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance PLoS One 8 2013 e81974
9. J.Y. Zhang, Z. Zhang, F. Lin, Z.S. Zou, R.N. Xu, and L. Jin Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B Hepatology 51 2010 81 91
10. T. Duhen, R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells Nat Immunol 10 2009 857 863
11. R. Sabat, W. Ouyang, and K. Wolk Therapeutic opportunities of the IL-22-IL-22R1 system Nat Rev Drug Discov 13 2014 21 38
12. J.M. Ramirez, N.C. Brembilla, O. Sorg, R. Chicheportiche, T. Matthes, and J.M. Dayer Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells Eur J Immunol 40 2010 2450 2459
13. S. Trifari, C.D. Kaplan, E.H. Tran, N.K. Crellin, and H. Spits Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells Nat Immunol 10 2009 864 871
14. X. Xiang, H. Gui, N.J. King, L. Cole, H. Wang, and Q. Xie IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver Immunol Cell Biol 90 2012 611 619
15. Y. Zhang, M.A. Cobleigh, J.Q. Lian, C.X. Huang, C.J. Booth, and X.F. Bai A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus Gastroenterology 141 2011 1897 1906
16. F.Q. Hou, Z. Zeng, and G.Q. Wang Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes Cell Biochem Biophys 64 2012 77 83
17. M.S. Padda, M. Sanchez, A.J. Akhtar, and J.L. Boyer Drug-induced cholestasis Hepatology 53 2011 1377 1387
18. C. Benichou Criteria of drug-induced liver disorders. Report of an international consensus meeting J Hepatol 11 1990 272 276
19. G.P. Aithal, P.B. Watkins, R.J. Andrade, D. Larrey, M. Molokhia, and H. Takikawa Case definition and phenotype standardization in drug-induced liver injury Clin Pharmacol Ther 89 2011 806 815
20. R.J. Fontana, P.B. Watkins, H.L. Bonkovsky, N. Chalasani, T. Davern, and J. Serrano Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct Drug Saf 32 2009 55 68
21. A.K. Daly, P.T. Donaldson, P. Bhatnagar, Y. Shen, I. Pe'er, and A. Floratos HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin Nat Genet 41 2009 816 819
22. J. Ozer, M. Ratner, M. Shaw, W. Bailey, and S. Schomaker The current state of serum biomarkers of hepatotoxicity Toxicology 245 2008 194 205
23. D.E. Kleiner, N.P. Chalasani, W.M. Lee, R.J. Fontana, H.L. Bonkovsky, and P.B. Watkins Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations Hepatology 59 2014 661 670
24. R. Taub Liver regeneration: from myth to mechanism Nat Rev Mol Cell Biol 5 2004 836 847
25. A. Katoonizadeh, F. Nevens, C. Verslype, J. Pirenne, and T. Roskams Liver regeneration in acute severe liver impairment: a clinicopathological correlation study Liver Int 26 2006 1225 1233
26. O. Park, H. Wang, H. Weng, L. Feigenbaum, H. Li, and S. Yin In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression Hepatology 54 2011 252 261
27. J. Zhao, Z. Zhang, Y. Luan, Z. Zou, Y. Sun, and Y. Li Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment Hepatology 59 2014 1331 1342
28. H. Park, Z. Li, X.O. Yang, S.H. Chang, R. Nurieva, and Y.H. Wang A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 Nat Immunol 6 2005 1133 1141
29. J. Li, X. Zhu, F. Liu, P. Cai, C. Sanders, and W.M. Lee Cytokine and autoantibody patterns in acute liver failure J Immunotoxicol 7 2010 157 164
30. D.N. Patel, C.A. King, S.R. Bailey, J.W. Holt, K. Venkatachalam, and A. Agrawal Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation J Biol Chem 282 2007 27229 27238
31. M.J. McGeachy, Y. Chen, C.M. Tato, A. Laurence, B. Joyce-Shaikh, and W.M. Blumenschein The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo Nat Immunol 10 2009 314 324
32. Y. Masubuchi, M. Bourdi, T.P. Reilly, M.L. Graf, J.W. George, and L.R. Pohl Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease Biochem Biophys Res Commun 304 2003 207 212
33. D.M. Dambach, S.K. Durham, J.D. Laskin, and D.L. Laskin Distinct roles of NF-kappaB p50 in the regulation of acetaminophen-induced inflammatory mediator production and hepatotoxicity Toxicol Appl Pharmacol 211 2006 157 165
34. V.J. Navarro, and J.R. Senior Drug-related hepatotoxicity N Engl J Med 354 2006 731 739
35. N.P. Chalasani, P.H. Hayashi, H.L. Bonkovsky, V.J. Navarro, W.M. Lee, and R.J. Fontana ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury Am J Gastroenterol 109 2014 950 966 quiz 967
36. Y.M. Mao, M.D. Zeng, Y. Chen, C.W. Chen, Q.C. Fu, and X. Cai Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study Zhonghua Gan Zang Bing Za Zhi 17 2009 847 851
37. X. Wang, R. Sun, H. Wei, and Z. Tian High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: Interaction of gammadelta T cells with macrophages Hepatology 57 2013 373 384
38. G. Paumgartner, and U. Beuers Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited Hepatology 36 2002 525 531
39. M. Tanaka, H. Nakura, T. Tateishi, M. Watanabe, S. Nakaya, and T. Kumai Ursodeoxycholic acid prevents hepatic cytochrome P450 isozyme reduction in rats with deoxycholic acid-induced liver injury J Hepatol 31 1999 263 270
40. R.A. Nathwani, and N. Kaplowitz Drug hepatotoxicity Clin Liver Dis 10 2006 207 217 vii